Trade Royalty Pharma plc - RPRX CFD

Add to favourite

28.10

1.01%

0.12

Low: 27.73

High: 28.1

Market Trading Hours* (UTC) Opens on Monday at 13:30

Mon - Fri: 13:30 - 20:00

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow

Trading сonditions

Spread

0.12

Long position overnight fee

-0.026179%

Short position overnight fee

0.003957%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

USD

Margin

Stock exchange

United States of America

Commission on trade

*Information provided by Capital.com

Royalty Pharma PLC ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats

Prev. Close*	27.82
Open*	27.75
1-Year Change*	-22.59%
Day's Range*	27.73 - 28.1
52 wk Range	25.92-39.25
Average Volume (10 days)	2.13M
Average Volume (3 months)	48.15M
Market Cap	16.80B
P/E Ratio	70.58
Shares Outstanding	599.29M
Revenue	2.32B
EPS	0.40
Dividend (Yield %)	2.85307
Beta	0.42
Next Earnings Date	Feb 13, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 19, 2024	28.10	0.51	1.85%	27.59	28.12	27.59
Apr 18, 2024	27.82	0.44	1.61%	27.38	27.97	27.23
Apr 17, 2024	27.55	0.08	0.29%	27.47	27.72	27.25
Apr 16, 2024	27.37	-0.63	-2.25%	28.00	28.00	27.37
Apr 15, 2024	28.18	-0.09	-0.32%	28.27	28.54	27.96
Apr 12, 2024	28.16	-0.57	-1.98%	28.73	28.89	27.80
Apr 11, 2024	28.98	-0.19	-0.65%	29.17	29.45	28.34
Apr 10, 2024	29.37	-0.12	-0.41%	29.49	29.64	29.09
Apr 9, 2024	29.65	0.68	2.35%	28.97	29.67	28.97
Apr 8, 2024	29.16	0.12	0.41%	29.04	29.25	28.99
Apr 5, 2024	29.13	0.57	2.00%	28.56	29.47	28.49
Apr 4, 2024	28.66	-0.14	-0.49%	28.80	29.11	28.47
Apr 3, 2024	28.74	-0.52	-1.78%	29.26	29.50	28.62
Apr 2, 2024	29.37	-0.46	-1.54%	29.83	29.85	29.36
Apr 1, 2024	29.84	-0.57	-1.87%	30.41	30.41	29.80
Mar 28, 2024	30.31	-0.12	-0.39%	30.43	30.73	30.25
Mar 27, 2024	30.38	0.03	0.10%	30.35	30.42	30.12
Mar 26, 2024	30.15	0.11	0.37%	30.04	30.32	29.96
Mar 25, 2024	30.23	0.16	0.53%	30.07	30.42	30.01
Mar 22, 2024	30.21	-0.20	-0.66%	30.41	30.61	30.17

Royalty Pharma plc Events

Time (UTC)	Country	Event
Tuesday, May 7, 2024
Time (UTC) 12:30	Country US	Event Q1 2024 Royalty Pharma PLC Earnings Release Q1 2024 Royalty Pharma PLC Earnings Release Forecast - Previous -
Thursday, May 9, 2024
Time (UTC) 12:00	Country US	Event Q1 2024 Royalty Pharma PLC Earnings Call Q1 2024 Royalty Pharma PLC Earnings Call Forecast - Previous -
Friday, June 21, 2024
Time (UTC) 13:00	Country US	Event Royalty Pharma PLC Annual Shareholders Meeting Royalty Pharma PLC Annual Shareholders Meeting Forecast - Previous -
Tuesday, August 6, 2024
Time (UTC) 12:30	Country US	Event Q2 2024 Royalty Pharma PLC Earnings Release Q2 2024 Royalty Pharma PLC Earnings Release Forecast - Previous -

View all events

Annual
Quarterly

	2022	2021	2020	2019	2018
Total revenue	2237.22	2289.46	2122.35	1814.25	1794.89
Revenue	2237.22	2289.46	2122.35	1814.25	1794.89
Total Operating Expense	1930.15	858.748	557.454	-808.922	430.448
Selling/General/Admin. Expenses, Total	227.303	182.826	181.715	103.439	61.906
Research & Development	177.106	200.084	26.289	83.036	392.609
Depreciation / Amortization	5.67	22.996	23.058	23.924	33.267
Other Operating Expenses, Total	904.244	452.842	230.839	-1019.32	-57.334
Operating Income	307.065	1430.71	1564.9	2623.18	1364.45
Interest Income (Expense), Net Non-Operating	-62.246	-183.836	139.376	-162.15	154.927
Gain (Loss) on Sale of Assets				0	0
Other, Net	-14.755	-5.678	-2.321	0.393	-1.518
Net Income Before Taxes	230.064	1241.2	1701.95	2461.42	1517.85
Net Income After Taxes	230.064	1241.2	1701.95	2461.42	1517.85
Minority Interest	-187.232	-621.473	-726.914	-112.884	-140.126
Net Income Before Extra. Items	42.832	619.728	975.04	2348.53	1377.73
Net Income	42.832	619.728	975.04	2348.53	1377.73
Income Available to Common Excl. Extra. Items	42.832	619.728	495.198	2348.53	1377.73
Income Available to Common Incl. Extra. Items	42.832	619.728	495.198	2348.53	1377.73
Diluted Net Income	42.832	619.728	495.198	2348.53	1377.73
Diluted Weighted Average Shares	437.972	414.802	375.455	595.383	595.383
Diluted EPS Excluding Extraordinary Items	0.0978	1.49403	1.31893	3.94458	2.31402
Dividends per Share - Common Stock Primary Issue	0.76	0.68	0.3	0	0
Diluted Normalized EPS	1.50388	1.49403	1.74655	3.94458	2.31402
Unusual Expense (Income)	615.827	0	95.553
Total Adjustments to Net Income			-479.842

	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022
Total revenue	538.202	683.971	565.748	573.463	535.955
Revenue	538.202	683.971	565.748	573.463	535.955
Total Operating Expense	289.362	204.999	1048.4	381.253	158.163
Selling/General/Admin. Expenses, Total	47.634	85.695	73.228	50.692	51.843
Research & Development	0.5	0.5	50.5	25.5	0.606
Depreciation / Amortization	0	0	0	0	0
Other Operating Expenses, Total	241.228	118.804	308.848	305.061	105.714
Operating Income	248.84	478.972	-482.655	192.21	377.792
Interest Income (Expense), Net Non-Operating	101.405	32.93	-126.21	39.002	114.84
Other, Net	1.091	-2.813	-1.165	-10.798	-1.035
Net Income Before Taxes	351.336	509.089	-610.03	220.414	491.597
Net Income After Taxes	351.336	509.089	-610.03	220.414	491.597
Minority Interest	-123.711	-168.334	153.946	-77.763	-187.093
Net Income Before Extra. Items	227.625	340.755	-456.084	142.651	304.504
Net Income	227.625	340.755	-456.084	142.651	304.504
Income Available to Common Excl. Extra. Items	227.625	340.755	-456.084	142.651	304.504
Income Available to Common Incl. Extra. Items	227.625	340.755	-456.084	142.651	304.504
Diluted Net Income	305.674	464.012	-456.084	197.047	423.728
Diluted Weighted Average Shares	605.86	607.251	442.226	607.226	607.214
Diluted EPS Excluding Extraordinary Items	0.50453	0.76412	-1.03134	0.3245	0.69782
Dividends per Share - Common Stock Primary Issue	0.2	0.2	0.19	0.19	0.19
Diluted Normalized EPS	0.50453	0.76412	0.36122	0.3245	0.69782
Dilution Adjustment	78.049	123.257		54.396	119.224
Unusual Expense (Income)			615.827

Annual
Quarterly

	2022	2021	2020	2019	2018
Total Current Assets	2554.91	2878.21	2696.9	832.072	2608.55
Cash and Short Term Investments	2427.79	2803.27	2649.14	793.214	2386.03
Cash & Equivalents	1710.75	1541.05	1008.68	283.682	1924.21
Short Term Investments	717.04	1262.22	1640.46	509.532	461.821
Total Receivables, Net	36.597	68.309	39.166	38.766	198.627
Accounts Receivable - Trade, Net	16.83	53.286	33.155	33.525	35.996
Other Current Assets, Total	90.52	6.631	8.596	0.092	23.895
Total Assets	16813.5	17515.9	16020.3	12449.9	11370.1
Intangibles, Net	0	5.67	28.666	51.724	75.648
Long Term Investments	14228.9	14627.8	13266.1	11478.1	8666.83
Other Long Term Assets, Total	29.629	4.145	28.597	87.95	19.111
Total Current Liabilities	1166.78	171.25	307.887	333.417	580.172
Payable/Accrued	7.906	5.62	10.775	11.177	4.477
Notes Payable/Short Term Debt	0	0	0	0	0
Current Port. of LT Debt/Capital Leases	997.512		0	281.984	281.436
Other Current Liabilities, Total	107.203	107.934	144.966	40.256	294.259
Total Liabilities	11185.3	11739.3	11201.5	6344.34	6881.93
Total Long Term Debt	6118.81	7096.07	5816.58	5956.14	6237.9
Long Term Debt	6118.81	7096.07	5816.58	5956.14	6237.9
Minority Interest	3897.22	4471.95	5077.04	35.883	63.865
Other Liabilities, Total	2.5		0	18.902	0
Total Equity	5628.15	5776.59	4818.78	6105.56	4488.21
Common Stock	0.10716	0.10617	0.10222	3282.52	3282.52
Retained Earnings (Accumulated Deficit)	1964.69	2255.18	1920.64	2825.21	1215.95
Treasury Stock - Common	-2.806	-2.715	-2.317	-4.266	0
Unrealized Gain (Loss)	0	16.491	34.395	2.093	-10.255
Total Liabilities & Shareholders’ Equity	16813.5	17515.9	16020.3	12449.9	11370.1
Total Common Shares Outstanding	443.166	432.963	388.135	350.833	350.833
Accrued Expenses	54.162	57.696	152.146
Additional Paid-In Capital	3666.16	3507.53	2865.96
Other Equity, Total	-0.00016	-0.00017	-0.00022

	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Total Current Assets	1728.6	2953.54	2631.22	2554.91	2342.12
Cash and Short Term Investments	1683.91	2908.09	2588.21	2427.79	2216.76
Cash & Equivalents	936.448	2173.08	1975.69	1710.75	991.628
Short Term Investments	747.46	735.01	612.522	717.04	1225.13
Total Receivables, Net	37.913	35.228	38.44	36.597	34.843
Accounts Receivable - Trade, Net	16.36	16.358	16.356	16.83	15.712
Other Current Assets, Total	6.784	10.224	4.57	90.52	90.515
Total Assets	15855.5	17121.5	17074.1	16813.5	17672.6
Intangibles, Net				0	0
Long Term Investments	14106.7	14138.5	14414.9	14228.9	15299.9
Other Long Term Assets, Total	20.212	29.408	28.03	29.629	30.613
Total Current Liabilities	127.933	1172.22	1116.88	1166.78	1131.62
Payable/Accrued	13.627	5.809	6.657	7.906	16.112
Accrued Expenses	12.595	54.162	13.199	54.162	13.199
Notes Payable/Short Term Debt	0	0	0	0	0
Other Current Liabilities, Total	101.711	112.881	98.582	107.203	105.731
Total Liabilities	9716.6	10839.8	11120.4	11185.3	11520.5
Total Long Term Debt	6131.19	6127.07	6122.94	6118.81	6114.68
Long Term Debt	6131.19	6127.07	6122.94	6118.81	6114.68
Minority Interest	3446.18	3532.02	3868.25	3897.22	4264.3
Total Equity	6138.92	6281.67	5953.75	5628.15	6152.1
Common Stock	0.108	0.10915	0.10816	0.10716	0.10717
Additional Paid-In Capital	4006.76	4031.24	3739.66	3666.16	3632.9
Retained Earnings (Accumulated Deficit)	2134.68	2252.95	2216.81	1964.69	2504.97
Treasury Stock - Common	-2.624	-2.629	-2.828	-2.806	-2.788
Other Equity, Total		-0.00015	-0.00016	-0.00016	-0.00017
Total Liabilities & Shareholders’ Equity	15855.5	17121.5	17074.1	16813.5	17672.6
Total Common Shares Outstanding	445.843	450.352	448.287	443.166	441.104
Unrealized Gain (Loss)				0	16.904
Other Liabilities, Total	11.3	8.5	12.3	2.5	9.9
Current Port. of LT Debt/Capital Leases	0	999.37	998.441	997.512	996.583

Annual
Quarterly

	2022	2021	2020	2019	2018
Cash From Operating Activities	2143.98	2017.54	2034.63	1667.24	1618.32
Cash Receipts	2650.07	2545.79	2329.23	2105.2	2287.91
Cash Payments	-222.969	-184.511	-179.709	-88.524	-72.535
Cash Interest Paid	-170.139	-130.43	-103.196	-254.964	-267.657
Changes in Working Capital	-112.982	-213.318	-11.699	-94.471	-329.401
Cash From Investing Activities	-1029.42	-1870.28	-2759.32	-2116.14	303.424
Capital Expenditures	-1741.64	-2191.5	-2182.25	-1721.29	-269.593
Other Investing Cash Flow Items, Total	712.219	321.222	-577.074	-394.851	573.017
Cash From Financing Activities	-944.856	385.112	1487.17	-1191.63	-1379.1
Financing Cash Flow Items	-611.534	-602.237	-989.716	-897.626	-1085.1
Issuance (Retirement) of Debt, Net	0	1272.53	680.634	-294	-294
Net Change in Cash	169.703	532.368	762.481	-1640.53	542.64
Total Cash Dividends Paid	-333.322	-285.184	-112.49
Issuance (Retirement) of Stock, Net	0	0	1908.74

	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
Cash From Operating Activities	1033.84	2143.98	1574.05	1035.22	460.27
Cash Receipts	1171.94	2650.07	1967.91	1285.45	674.716
Cash Payments	-86.846	-222.969	-141.653	-93.003	-48.902
Cash Interest Paid	-82.589	-170.139	-169.476	-86.88	-86.216
Changes in Working Capital	31.335	-112.982	-82.734	-70.342	-79.328
Cash From Investing Activities	-558.526	-1029.42	-1444.16	-19.013	11.165
Capital Expenditures	-601.705	-1741.64	-1491.4	-175.093	-0.085
Other Investing Cash Flow Items, Total	43.179	712.219	47.236	156.08	11.25
Cash From Financing Activities	-210.373	-944.856	-679.306	-449.22	-220.966
Financing Cash Flow Items	-121.74	-611.534	-430.185	-283.908	-138.703
Total Cash Dividends Paid	-88.633	-333.322	-249.121	-165.312	-82.263
Issuance (Retirement) of Debt, Net		0	0
Net Change in Cash	264.938	169.703	-549.42	566.989	250.469
Issuance (Retirement) of Stock, Net		0

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Royalty Pharma plc Company profile

About Royalty Pharma plc

Royalty Pharma plc is engaged in investing in late stage biopharmaceutical products. The Company invests in academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The Company’s portfolio of pharmaceutical investment includes investments in commercial products and development-stage product candidates. Its portfolio investments include AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko, Trikafta and OXLUMO.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Royalty Pharma plc revenues increased 8% to $2.29B. Net income applicable to common stockholders increased 25% to $619.7M. Revenues reflect Income from financial royalty assets increase of 5% to $2.07B, Other royalty income increase from $19M to $53.1M, Revenue from intangible royalty assets increase of 19% to $171.2M. Net income benefited from Other operating expenses decrease from $65.1M (expense) to $0K.

Industry:

Pharmaceuticals (NEC)

110 East 59th Street
NEW YORK
NEW YORK 10022
US

Income Statement

Annual
Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024